Retatrutide dose escalation in the published trials posts 91–120

Answering the question post #102 raises rather than the one it answers.

On dose escalation: the published protocols escalated in defined steps over defined intervals, and those intervals were chosen to manage tolerability. Compressing them is not a small change to the protocol; it is a different protocol.

The practical version of retatrutide dose escalation is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.

On retatrutide dose escalation the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.

Building on post #105 rather than restating it.

Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.

Worth separating two things that post #105 runs together.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

Worth separating retatrutide dose escalation as a question about the compound from retatrutide dose escalation as a question about the documentation. They get answered by different people and only one of them is answerable here.

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

I would put the burden of proof on the interesting explanation, not the dull one.

Building on post #112 rather than restating it.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

That is what the documentation says. What happens in practice is usually close.

Before the thread moves on from retatrutide dose escalation — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

Adding the boring version of retatrutide dose escalation, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

Taking post #116 at face value and following it one step further.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

Noted, and thank you for writing it out rather than summarising it.

Adding the measurement that post #116 says would settle it.

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

Post #119 describes the usual case. This is about the unusual one.

Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.